Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.
Cladribine tablets
Disease-modifying therapy
Holistic management
Multiple sclerosis
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
17
11
2023
accepted:
09
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune reconstitution therapy. In contrast to most high-efficacy DMTs, which act via continuous immunosuppression, two short courses of oral treatment with CladT at the beginning of years 1 and 2 of treatment provide long-term control of MS disease activity in responders to treatment, without the need for any further pharmacological treatment for several years. Although the labelling for CladT does not provide guidance beyond the initial treatment courses, real-world data on the therapeutic use of CladT from registries of previous clinical trial participants and patients treated in routine practice indicate that MS disease activity is controlled for a period of years beyond this time for a substantial proportion of patients. Moreover, this clinical experience has provided useful information on how to initiate and manage treatment with CladT. In this article we, a group of expert neurologists from France, provide recommendations on the initiation of CladT in DMT-naïve patients, how to switch from existing DMTs to CladT for patients with continuing MS disease activity, how to manage patients during the first 2 years of treatment and finally, how to manage patients with or without MS disease activity in years 3, 4 and beyond after initiating treatment with CladT. We believe that optimisation of the use of CladT beyond its initial courses of treatment will maximise the benefits of this treatment, especially early in the course of MS when suppression of focal inflammation in the CNS is a clinical priority to limit MS disease progression.
Identifiants
pubmed: 38488979
doi: 10.1007/s40120-024-00589-7
pii: 10.1007/s40120-024-00589-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Future Med. 2022. https://doi.org/10.2217/nmt-2021-0058 . (accessed January 2024).
doi: 10.2217/nmt-2021-0058
AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? a narrative review. Neurol Ther. 2020;9:55–66.
pubmed: 32297127
pmcid: 7229056
doi: 10.1007/s40120-020-00187-3
Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol Ther. 2019;8:13–23.
pubmed: 30875021
pmcid: 6534637
doi: 10.1007/s40120-019-0129-0
Casanova B, Quintanilla-Bordás C, Gascón F. Escalation vs. early intense therapy in multiple sclerosis. J Pers Med. 2022;12:119.
pubmed: 35055434
pmcid: 8778390
doi: 10.3390/jpm12010119
Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419836913.
pubmed: 30944586
pmcid: 6440030
doi: 10.1177/1756286419836913
European Medicines Agency. Lemtrada. Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. Available at https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada . Accessed 23 Feb 2024.
European Medicines Agency. Mavenclad. Summary of Product Characteristics. Available at https://www.ema.europa.eu/documents/product-information/mavenclad-epar-product-information_en.pdf . Accessed 23 Feb 2024.
Clavelou P, Castelnovo G, Pourcher V, et al. Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis. Neurol Ther. 2023;12:1457–76.
pubmed: 37382841
pmcid: 10444734
doi: 10.1007/s40120-023-00496-3
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.
pubmed: 29353550
doi: 10.1177/1352458517751049
Adamec I, Brecl Jakob G, Rajda C, et al. Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers. J Neuroimmunol. 2023;382: 578164.
pubmed: 37536052
doi: 10.1016/j.jneuroim.2023.578164
Aerts S, Khan H, Severijns D, Popescu V, Peeters LM, Van Wijmeersch B. Safety and effectiveness of cladribine tablets for multiple sclerosis: results from a single-center real-world cohort. Mult Scler Relat Disord. 2023;75: 104735.
pubmed: 37192586
doi: 10.1016/j.msard.2023.104735
Zanetta C, Rocca MA, Meani A, et al. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. 2023;270:3553–64.
pubmed: 37027018
pmcid: 10080181
doi: 10.1007/s00415-023-11700-7
Petracca M, Ruggieri S, Barbuti E, et al. Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study. Neurol Ther. 2022;11:1193–208.
pubmed: 35653061
pmcid: 9338179
doi: 10.1007/s40120-022-00364-6
Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61: 103755.
pubmed: 35483129
doi: 10.1016/j.msard.2022.103755
Song Y, Wang Y, Wong SL, Yang D, Sundar M, Tundia N. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Mult Scler Relat Disord. 2023;79: 105052.
pubmed: 37832254
doi: 10.1016/j.msard.2023.105052
Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr. 2022;172:365–72.
pubmed: 35451662
pmcid: 9026047
doi: 10.1007/s10354-022-00931-4
Sorensen PS, Pontieri L, Joensen H, et al. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study. Mult Scler Relat Disord. 2023;70: 104491.
pubmed: 36623393
doi: 10.1016/j.msard.2022.104491
De Sèze J, Suchet L, Mekies C, et al. The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus. Neurol Ther. 2023;12:351–69.
pubmed: 36564664
doi: 10.1007/s40120-022-00430-z
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.
pubmed: 20089960
doi: 10.1056/NEJMoa0902533
Oreja-Guevara C, Brownlee W, Celius EG, et al. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord. 2023;69: 104459.
pubmed: 36565573
doi: 10.1016/j.msard.2022.104459
Alroughani R, Inshasi J, Al-Asmi A, et al. Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the Gulf Region. Neurol Ther. 2020;9:265–80.
pubmed: 32564333
pmcid: 7606397
doi: 10.1007/s40120-020-00201-8
Brownlee W, Amin A, Ashton L, Herbert A. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study. Mult Scler Relat Disord. 2023;79: 104951.
pubmed: 37639781
doi: 10.1016/j.msard.2023.104951
Adveva. Available at https://www.adveva.co.uk/en/about-mavenclad/getting-to-know-mavenclad.html . Accessed 23 Feb 2024.
Spelman T, Ozakbas S, Alroughani R, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler. 2023;29:221–35.
pubmed: 36433775
doi: 10.1177/13524585221137502
Brochet B, Solari A, Lechner-Scott J, et al. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023;29:1808–18.
pubmed: 37978852
pmcid: 10687821
doi: 10.1177/13524585231205962
Inshasi J, Farouk S, Shatila A, et al. Multicentre observational study of treatment satisfaction with cladribine tablets in the management of relapsing multiple sclerosis in the Arabian Gulf: the CLUE Study. Neurol Ther. 2023;12:1309–18.
pubmed: 37289421
pmcid: 10310633
doi: 10.1007/s40120-023-00497-2
Rau D, Müller B, Übler S. Evaluation of patient-reported outcomes in patients with relapsing multiple sclerosis treated with cladribine tablets in the CLAWIR study: 12-month interim analysis. Adv Ther. 2023;40:5547–56.
pubmed: 37776477
pmcid: 10611608
doi: 10.1007/s12325-023-02682-z
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25:819–27.
pubmed: 29716436
doi: 10.1177/1352458518771875
Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.
pubmed: 34422112
pmcid: 8377320
doi: 10.1177/17562864211039648
Rojas JI, Patrucco L, Alonso R, et al. Effectiveness and safety of early high-efficacy versus escalation therapy in relapsing-remitting multiple sclerosis in Argentina. Clin Neuropharmacol. 2022;45:45–51.
pubmed: 35579483
doi: 10.1097/WNF.0000000000000503
Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269:1670–7.
pubmed: 34626224
doi: 10.1007/s00415-021-10836-8
Simonsen CS, Flemmen HØ, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12: 693017.
pubmed: 34220694
pmcid: 8248666
doi: 10.3389/fneur.2021.693017
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536–41.
pubmed: 30776055
pmcid: 6515582
doi: 10.1001/jamaneurol.2018.4905
Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–87.
pubmed: 30644981
pmcid: 6439772
doi: 10.1001/jama.2018.20588
Freedman MS, Leist TP, Comi G, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017;3:2055217317732802.
pubmed: 29051829
pmcid: 5637982
Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269:5382–94.
pubmed: 35608658
pmcid: 9489547
doi: 10.1007/s00415-022-11193-w
Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36:1285–99.
pubmed: 36350491
pmcid: 9645316
doi: 10.1007/s40263-022-00965-7
He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16.
pubmed: 32199096
doi: 10.1016/S1474-4422(20)30067-3
Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95:e1041–51.
pubmed: 32636328
doi: 10.1212/WNL.0000000000010135
Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78:1197–204.
pubmed: 34398221
doi: 10.1001/jamaneurol.2021.2738
Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4 Multiple Sclerosis):901–21.
pubmed: 23917093
Gallo P, Van Wijmeersch B, ParadigMS Group. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur J Neurol. 2015;22(Suppl 2):14–21.
pubmed: 26374509
doi: 10.1111/ene.12799
Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27.
pubmed: 29523094
pmcid: 5845207
doi: 10.1186/s12883-018-1026-3
Hughes J, Jokubaitis V, Lugaresi A, et al. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis. JAMA Neurol. 2018;75:1407–15.
pubmed: 30083762
pmcid: 6248114
doi: 10.1001/jamaneurol.2018.2109
Morrow SA, Riccio P, Vording N, Rosehart H, Casserly C, MacDougall A. A mindfulness group intervention in newly diagnosed persons with multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2021;52: 103016.
pubmed: 34020388
doi: 10.1016/j.msard.2021.103016
Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler. 2012;18:210–8.
pubmed: 21865415
doi: 10.1177/1352458511419702
Renner A, Baetge SJ, Filser M, Penner IK. Working ability in individuals with different disease courses of multiple sclerosis: factors beyond physical impairment. Mult Scler Relat Disord. 2020;46: 102559.
pubmed: 33035965
doi: 10.1016/j.msard.2020.102559
He A, Spelman T, Manouchehrinia A, Ciccarelli O, Hillert J, McKay K. Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study. J Neurol Neurosurg Psychiatry. 2023;94:284–9.
pubmed: 36600595
doi: 10.1136/jnnp-2022-330169
Bigaut K, Cohen M, Durand-Dubief F, et al. How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP). Mult Scler Relat Disord. 2021;53: 103076.
pubmed: 34161898
doi: 10.1016/j.msard.2021.103076
Wood CH, Robertson NP, Htet ZM, Tallantyre EC. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Mult Scler Relat Disord. 2022;58: 103492.
pubmed: 35066268
doi: 10.1016/j.msard.2022.103492
Caldito NG, O’Leary S, Stuve O. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation. Mult Scler. 2021;27(8):1306–8.
pubmed: 33620273
doi: 10.1177/1352458520988149
Borrelli S, Mathias A, Goff GL, Pasquier RD, Théaudin M, Pot C. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis. Mult Scler Relat Disord. 2022;63: 103887.
pubmed: 35636269
doi: 10.1016/j.msard.2022.103887
Malpas CB, Roos I, Sharmin S, et al. Multiple sclerosis relapses following cessation of fingolimod. Clin Drug Investig. 2022;42:355–64.
pubmed: 35303292
pmcid: 8989797
doi: 10.1007/s40261-022-01129-7
Roos I, Malpas C, Leray E, et al. Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. Neurology. 2022;99:e1926–44.
pubmed: 35977837
pmcid: 9620810
doi: 10.1212/WNL.0000000000201029
Hellwig K, Tokic M, Thiel S, et al. Multiple sclerosis disease activity and disability following cessation of fingolimod for pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023;10: e200126.
pubmed: 37217309
pmcid: 10202774
doi: 10.1212/NXI.0000000000200110
Callens A, Leblanc S, Le Page E, et al. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: a retrospective study. Mult Scler Relat Disord. 2022;66: 104066.
pubmed: 35908450
doi: 10.1016/j.msard.2022.104066
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.
pubmed: 30956686
pmcid: 6444403
doi: 10.1177/1756286419837809
Auer M, Zinganell A, Hegen H, et al. Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years. Sci Rep. 2021;11:23317.
pubmed: 34857795
pmcid: 8639988
doi: 10.1038/s41598-021-02665-6
de Stefano N, Barkhof F, Montalban X, et al. Early reduction of MRI activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflamm. 2022;9: e1187.
pubmed: 35701185
pmcid: 9197134
doi: 10.1212/NXI.0000000000001187
Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–74.
pubmed: 30885375
doi: 10.1016/j.msard.2019.01.038
De Stefano N, Sormani MP, Giovannoni G, et al. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies. Mult Scler. 2022;28:111–20.
pubmed: 33969750
doi: 10.1177/13524585211010294
Comi G, Cook SD, Giovannoni G, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol. 2013;260:1136–46.
pubmed: 23263473
doi: 10.1007/s00415-012-6775-0
Schippling S, Sormani MP, De Stefano N, et al. CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo. Mult Scler J. 2018;24(S2):258 (Abstract).
Yamout B, Giovannoni G, Magyari M, et al. Preservation of relapse-free status in year 2 of treatment with cladribine tablets by relapse-free status in year 1. Eur J Neurol. 2020;27(Suppl. 1):482 (Abstract).
Bain J, Oh J, Jones A, et al. Early real-world safety, tolerability, and efficacy of cladribine tablets: a single center experience. Mult Scler. 2020;26(3 Suppl):274 (Abstract).
Barbuti E, Ianniello A, Nistri R, et al. Real world experience with cladribine at S Andrea hospital of Rome. J Neurol Sci. 2020;429(Suppl):118113 (Abstract).
Barros A, Santos M, Sequeira J, et al. Effectiveness of cladribine in multiple sclerosis – clinical experience of two tertiary centers. Mult Scler. 2020;26(3 Suppl):278 (Abstract).
Eichau S, Dotor J, Lopez-Ruiz R. Cladribine in a real world setting. The real patients Mult Scler. 2021;27(2 Suppl):713 (Abstract).
Horáková D, Vachová M, Tvaroh A, et al. Oral cladribine in the treatment of multiple sclerosis—data from the national registry ReMuS® registry. Cesk Slov Neurol N. 2021;86:555–61.
Nicholas J, Mackie DS, Costantino H, et al. A cross-sectional survey evaluating cladribine tablets treatment patterns among patients with multiple sclerosis across the US enrolled in the MS lifelines patient support program. Neurology. 2022;98(18 Suppl):2868 (Abstract).
Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler. 2022;28:257–68.
pubmed: 33975489
doi: 10.1177/13524585211012227
Rosengren V, Ekström E, Forsberg L, et al. Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study “immunomodulation and multiple sclerosis epidemiology 10” (IMSE 10). Mult Scler. 2021;27(2 Suppl):623 (Abstract).
Thakre M, Inshasi J. Real world experience of oral immune reconstitution therapy (cladribine) in the treatment of multiple sclerosis in the United Arab Emirates. Mult Scler. 2020;26(3 Suppl):185 (Abstract).
Brownlee W, Haghikia A, Hayward B, et al. Comparative effectiveness of cladribine versus fingolimod in the treatment of highly active relapsing multiple sclerosis. Mult Scler Rleat Disord. 2023;76: 104791.
doi: 10.1016/j.msard.2023.104791
Butzkueven H, Spelman T, Hodgkinson S, et al. Real-world experience with cladribine in the MSBase registry. Mult Scler. 2021;27(2 Suppl):681 (Abstract).
Santos M, Sequeira J, Abreu P, et al. Safety and effectiveness of cladribine in multiple sclerosis: real-world clinical experience from 5 tertiary hospitals in Portugal. Clin Neuropharmacol. 2023;46:105–11.
pubmed: 37191564
doi: 10.1097/WNF.0000000000000552
Giovannoni G, Boyko A, Correale J, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023;29:719–30.
pubmed: 37012898
pmcid: 10176755
doi: 10.1177/13524585231161494
Patti F, Visconti A, Capacchione A, Roy S, Trojano M, CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685.
pubmed: 32587633
pmcid: 7294475
doi: 10.1177/1756286420922685
Allen-Philbey K, De Trane S, MacDougall A, et al. Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Ther Adv Neurol Disord. 2023;16:17562864231200628.
pubmed: 37954917
pmcid: 10638874
doi: 10.1177/17562864231200627
Magalashvili D, Mandel M, Dreyer-Alster S, et al. Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4. J Neuroimmunol. 2022;372: 577966.
pubmed: 36162338
doi: 10.1016/j.jneuroim.2022.577966
Signori A, Saccà F, Lanzillo R, et al. Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7: e878.
pubmed: 32801167
pmcid: 7641098
doi: 10.1212/NXI.0000000000000878
Meuth SG, Bayas A, Kallmann B, et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022;23:1503–10.
pubmed: 35930260
doi: 10.1080/14656566.2022.2106783
Wiendl H, Schmierer K, Hodgkinson S, et al. Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS Substudy. Neurol Neuroimmunol Neuroinflamm. 2022;10: e200048.
pubmed: 36411081
pmcid: 9679889
doi: 10.1212/NXI.0000000000200048
Ruschil C, Gabernet G, Kemmerer CL, et al. Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients. Front Immunol. 2023;14:1133967.
pubmed: 36960053
pmcid: 10028280
doi: 10.3389/fimmu.2023.1133967
Moser T, Schwenker K, Seiberl M, et al. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol. 2020;7:2199–212.
pubmed: 33002321
pmcid: 7664268
doi: 10.1002/acn3.51206
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:1266–71.
pubmed: 29991490
doi: 10.1136/jnnp-2017-317411
Seiberl M, Feige J, Hilpold P, et al. Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting. Int J Mol Sci. 2023;24:4067.
pubmed: 36835478
pmcid: 9961994
doi: 10.3390/ijms24044067
Centonze D, Amato MP, Brescia Morra V, et al. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Ther Adv Neurol Disord. 2023;16:17562864231183220.
pubmed: 37434878
pmcid: 10331342
doi: 10.1177/17562864231183221
Habek M, Drulovic J, Brecl Jakob G, et al. Treatment with cladribine tablets beyond year 4: a position statement by southeast european multiple sclerosis centers. Neurol Ther. 2023;12:25–37.
pubmed: 36394714
doi: 10.1007/s40120-022-00422-z
Meca-Lallana V, García Domínguez JM, López Ruiz R, et al. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther. 2022;11:1475–88.
pubmed: 36068429
pmcid: 9447968
doi: 10.1007/s40120-022-00394-0
Sørensen PS, Centonze D, Giovannoni G, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1756286420935019.
pubmed: 32636933
pmcid: 7318823
doi: 10.1177/1756286420935019
Petrou P, Achiron A, Cohen EG, et al. Practical recommendations on treatment of multiple sclerosis with cladribine: an Israeli Experts Group Viewpoint. J Neurol. 2023;270:5188–95.
pubmed: 37436562
doi: 10.1007/s00415-023-11846-4
Río J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009;15:848–53.
pubmed: 19542263
doi: 10.1177/1352458509104591
Tutuncu M, Altintas A, Dogan BV, et al. The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study. Acta Neurol Belg. 2021;121:1693–8.
pubmed: 32865702
doi: 10.1007/s13760-020-01476-2
Gasperini C, Prosperini L, Rovira À, et al. Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. Eur J Neurol. 2021;28:2533–42.
pubmed: 33786942
doi: 10.1111/ene.14845
Sormani MP, Rio J, Tintorè M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605–12.
pubmed: 23012253
doi: 10.1177/1352458512460605
Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87:134–40.
pubmed: 27306626
doi: 10.1212/WNL.0000000000002830
Sormani MP, Freedman MS, Aldridge J, Marhardt K, Kappos L, De Stefano N. MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. Mult Scler Relat Disord. 2021;49: 102790.
pubmed: 33571946
doi: 10.1016/j.msard.2021.102790
Kunchok A, Lechner-Scott J, Granella F, et al. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Mult Scler. 2021;27:695–705.
pubmed: 32639855
doi: 10.1177/1352458520936823
Ruggieri S, Prosperini L, Al-Araji S, et al. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study. J Neurol Neurosurg Psychiatry. 2024;95:142–50.
pubmed: 37775266
doi: 10.1136/jnnp-2023-331920
Keenan A, Gandhi K, Le H, et al. Prognostic value of the magnims score for assessment of disease modifying therapy in patients with relapsing multiple sclerosis treated with ponesimod. In: Abstract/Poster Presented at the 2022 Meeting of the Consortium of Multiple Sclerosis Centers, National Harbor, Maryland, USA, June 1–4 2022. Available at https://cmsc.confex.com/cmsc/2022/meetingapp.cgi/Paper/8094 . Accessed 23 Feb 2024.
Jamroz-Wiśniewska A, Zajdel R, Słowik A, et al. Modified Rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients. J Clin Med. 2021;10:1830.
pubmed: 33922368
pmcid: 8122749
doi: 10.3390/jcm10091830
Río J, Rovira À, Gasperini C, et al. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. J Neurol. 2022;269:452–9.
pubmed: 34596743
doi: 10.1007/s00415-021-10823-z
Hyun JW, Kim SH, Jeong IH, et al. Utility of the Rio score and modified Rio score in Korean patients with multiple sclerosis. PLoS ONE. 2015;10: e0129243.
pubmed: 26010897
pmcid: 4444088
doi: 10.1371/journal.pone.0129243